Cue Biopharma Inc (CUE)

May 12, 2025

Cue Biopharma (CUE) Reports Revenue Miss for Q1 2025 | CUE Stock News - GuruFocus

May 12, 2025

May 12, 2025

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq

May 12, 2025

May 12, 2025

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times

May 12, 2025

May 08, 2025

Cue Biopharma (CUE) Schedules Virtual Investor Event to Showcase Biologics Platform | CUE Stock News - GuruFocus

May 08, 2025

May 08, 2025

Cue Biopharma to Host Virtual Investor Event on May 15, 2025 - The Manila Times

May 08, 2025

May 05, 2025

Cue Biopharma to Participate in Fireside Chat at the Citizens Li - GuruFocus

May 05, 2025

May 05, 2025

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference - The Manila Times

May 05, 2025

May 05, 2025

Cue Biopharma Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView

May 05, 2025

May 05, 2025

Cue Biopharma Reveals Latest Immunotherapy Progress: Boehringer Partnership and Pipeline Details Coming - Stock Titan

May 05, 2025

May 02, 2025

Geode Capital Management LLC Grows Stake in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World

May 02, 2025

May 02, 2025

LPL Financial LLC Has $47,000 Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World

May 02, 2025

May 01, 2025

Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance

May 01, 2025

Apr 24, 2025

CUECue Biopharma Inc Latest Stock News & Market Updates - Stock Titan

Apr 24, 2025

Apr 21, 2025

Cue Biopharma stock holds $2 target, Market Outperform rating - Investing.com Australia

Apr 21, 2025

Apr 21, 2025

Cue Biopharma stock holds $2 target, Market Outperform rating By Investing.com - Investing.com South Africa

Apr 21, 2025

Apr 17, 2025

Petri Dish: Roche unloads drug to Cambridge biotech, Cue and Boehringer link up - The Business Journals

Apr 17, 2025

Apr 16, 2025

Cue Biopharma stock falls after pricing capital raise of $20M via securities offering - MSN

Apr 16, 2025

Apr 16, 2025

Cue Biopharma Inc Announces $20 Million Public Offering Amidst C - GuruFocus

Apr 16, 2025

Apr 16, 2025

Boehringer and Cue Biopharma to develop autoimmune therapies - Pharmaceutical Technology

Apr 16, 2025

Apr 16, 2025

Boehringer Ingelheim, Cue Biopharma partner to develop next generation treatment for autoimmune,... - Medical Dialogues

Apr 16, 2025

Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Apr 15, 2025

Apr 15, 2025

Cue Biopharma (CUE) Partners with Boehringer Ingelheim to Advance B Cell Therapy | CUE Stock News - GuruFocus

Apr 15, 2025

Apr 15, 2025

Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News

Apr 15, 2025

Apr 15, 2025

Cue Biopharma Rises On Partnership With Boehringer To Develop CUE-501 For Autoimmune Diseases - Nasdaq

Apr 15, 2025

Apr 15, 2025

Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases - Contract Pharma

Apr 15, 2025

Apr 15, 2025

Boehringer Ingelheim and Cue Biopharma agree to advance CUE-501 for autoimmune diseases - BioWorld MedTech

Apr 15, 2025

Apr 15, 2025

Cue stock in focus after pact with Boehringer (CUE:NASDAQ) - Seeking Alpha

Apr 15, 2025

Apr 15, 2025

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - Lelezard

Apr 15, 2025

Apr 15, 2025

Boehringer and Cue Biopharma partner to develop next-generation treatments - The Pharma Letter

Apr 15, 2025

Apr 15, 2025

Cue Biopharma stock holds $2 target, JMP reiterates rating By Investing.com - Investing.com India

Apr 15, 2025

Apr 15, 2025

Cue Biopharma stock holds $2 target, JMP reiterates rating - Investing.com Australia

Apr 15, 2025

Apr 15, 2025

Cue Biopharma (CUE) Launches Public Offering of Common Stock and Warrants | CUE Stock News - GuruFocus

Apr 15, 2025

Apr 15, 2025

Cue Biopharma to Host Business Update Call and Webcast | CUE Sto - GuruFocus

Apr 15, 2025

Apr 15, 2025

Cue Biopharma Prices $20 Million Public Offering of Stock, Warrants - marketscreener.com

Apr 15, 2025

Apr 15, 2025

Boehringer Ingelheim and Cue Biopharma partner to develop next-g - GuruFocus

Apr 15, 2025

Apr 15, 2025

Cue Biopharma Announces Proposed Public Offering | CUE Stock New - GuruFocus

Apr 15, 2025

Apr 15, 2025

Cue Biopharma (CUE) Stock Dips Amid $20M Public Offering Announcement - GuruFocus

Apr 15, 2025

Apr 15, 2025

Cue Biopharma Prices About $20 Mln Public Offering - Nasdaq

Apr 15, 2025

Apr 14, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Pub - GuruFocus

Apr 14, 2025

Apr 14, 2025

Cue Biopharma Prices Common Stock And Warrants At $0.79 Per Share; Pre-Funded Warrants At $0.789 - MarketScreener

Apr 14, 2025

Apr 14, 2025

$20M Capital Raise: Inside Cue Biopharma's Latest Strategic Financing Move - Stock Titan

Apr 14, 2025

Apr 14, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - The Manila Times

Apr 14, 2025

Apr 14, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - Benzinga

Apr 14, 2025

Apr 14, 2025

Cue Biopharma launches public stock offering By Investing.com - Investing.com South Africa

Apr 14, 2025

Apr 14, 2025

Cue Biopharma inks deal with Boehringer Ingelheim By Investing.com - Investing.com South Africa

Apr 14, 2025

Apr 14, 2025

Boehringer, Cue Biopharma ink autoimmune therapy deal By Investing.com - Investing.com Canada

Apr 14, 2025